CSIMarket Company Name, Ticker, Suppliers, else..
 
Assertio Holdings inc   (NASDAQ: ASRT)
Other Ticker:  
 
 
Price: $0.6294 $0.01 1.222%
Day's High: $0.65 Week Perf: 8.52 %
Day's Low: $ 0.62 30 Day Perf: -13.7 %
Volume (M): 170 52 Wk High: $ 1.80
Volume (M$): $ 107 52 Wk Avg: $1.02
Open: $0.62 52 Wk Low: $0.51



 Market Capitalization (Millions $) 59
 Shares Outstanding (Millions) 94
 Employees 300
 Revenues (TTM) (Millions $) 125
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 0

Assertio Holdings Inc
Assertio Holdings Inc. remains committed to delivering high-quality products and to meeting the needs of its customers.

In summary, Assertio Holdings Inc. is a specialty pharmaceutical company that develops and markets drugs for the treatment of various diseases. The company has a strong focus on quality control and regulatory adherence, and is committed to bringing new and innovative products to market. Despite facing some challenges in recent years, the company remains a leader in the pharmaceutical industry and is poised for future growth and success.


   Company Address: 100 South Saunders Road Lake Forest 60045 IL
   Company Phone Number: 419?7106   Stock Exchange / Ticker: NASDAQ ASRT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALKS   -3.02%    
AMRX   -3.5%    
BHC   -9.96%    
INDV   -5.99%    
TEVA        3.82% 
VTRS        3.65% 
• View Complete Report
   



Clinical Study

Assessing the Clinical and Economic Impact of Assertios Rolvedon A Balanced Approach to Innovation in Oncology Suppo...

Published Fri, Dec 13 2024 1:00 PM UTC

Abstract: The therapeutic landscape for oncology patients necessitates innovative solutions that ensure efficacy, safety, and practicality in the administration of supportive care treatments. In an effort to enhance patient convenience, Assertio Holdings Inc conducted a clinical study evaluating the same-day dosing efficacy of Rolvedon (eflapegrastim-xnst) against the tradit...
Management Changes

?Assertio Holdings: Navigating Leadership Changes and Clinical Innovations in Oncology After Revenue Challenges?,

Published Thu, Dec 12 2024 1:00 PM UTC

Assertio Holdings: Strategic Leadership Changes and Clinical Innovations in Oncology Amid ChallengesAssertio Holdings, Inc., a notable player in the pharmaceutical landscape, is gearing up for a pivotal shift under new leadership while navigating clinical innovations in oncology. The recent appointments of Paul Schwichtenberg as Chief Technology Officer (CTO) and Mary Pietry...
Stock Market Announcement

Clarifying the Narrative: Assertio Holdings and Rolvedon Address Misconceptions Over Financial Practices

Published Mon, Nov 11 2024 12:30 PM UTC

In the fast-paced landscape of pharmaceuticals, assertions can ripple through markets and affect not just individual companies, but entire sectors. Recently, a press release from Assertio Holdings drew attention, addressing what the company termed false and baseless claims regarding its accounting practices related to Rolvedon, its leading oncology product. On October 4, 202...
Product Service News

Assertio Holdings Navigating Financial Challenges and Strategic Growth Amid Sector Dynamics

Published Fri, Oct 4 2024 8:05 PM UTC

In recent developments, Assertio Holdings, Inc. has disclosed the approval of inducement grants in compliance with NASDAQ Listing Rule 5635(c)(4). While these inducement grants typically aim to attract and retain essential personnel, Assertio s latest financial performance sheds light on the considerable challenges the organization faces, particularly regarding its return on...
Shares

Assertio Holdings, Inc. Bolsters Talent Acquisition with Inducement Grants, Investors Await Impact on Shares

Published Tue, Jul 9 2024 8:30 PM UTC

Assertio Holdings, Inc. recently granted RSUs and stock options to newly-hired employees in accordance with NASDAQ Listing Rule 5635(c)(4). The company, known for its comprehensive commercial capabilities in the pharmaceutical industry, awarded a total of 44,575 RSUs and 142,910 stock options to four individuals as part of their inducement grants on July 1, 2024.
With 9...






Assertio Holdings Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com